cognitieve aandoening (dementie) Alzheimer's Disease
Conditions
Interventions
None listed
Sponsors
Wageningen Research (voormalig DLO)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age > 65years old Specific inclusion criteria for Alzheimer patients: - A diagnosis of probable Alzheimer*s disease according to the NIA-AA guidelines, CDR (clinical dementia rating) 1 (mild dementia), established as part of normal patient care at the multidisciplinary Radboudumc memory clinic - Presence of a caregiver (spouse, child). - Able to provide written consent (consent will also be obtained from the caregiver). Specific inclusion criteria for healthy controls: - Absence of subjective or objective memory impairment, MOCA score >26.
Exclusion criteria
Exclusion criteria: - Any digestive tract disorder that is expected to interfere with this study (e.g. (partial) gastric resection, (hemi)colectomy, Crohn*s disease, ulcerative colitis, colon cancer) - Use of lipid lowering medication - Use of antacids - Dyslipidaemia - Known allergy for any of the food components used in the study (milk, cream, sugars) - Diabetic patients (Type I and II) - Blood clotting disorders - Drug abuse - Current smokers - Participation in other clinical trials in the past three months - Behavioural disturbances associated with dementia
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| ApoE phenotype will be determined by an APOE genotyping method based on Real Time PCR. This phenotype will not change and will therefore be determined only at baseline and not postprandial. | — |
Primary
| Measure | Time frame |
|---|---|
| Plasma chylomicron profiles and chylomicron-related proteins, such as ApoE and Abeta. | — |
Countries
Netherlands
Outcome results
None listed